Buzz Stocks: DuPont, Celldex Therapeutics, Inc., and Marvell Technology Group Ltd.

Today's stocks to watch include DuPont (NYSE:DD), Celldex Therapeutics, Inc. (NASDAQ:CLDX), and Marvell Technology Group Ltd. (NASDAQ:MRVL)

Mar 7, 2016 at 10:08 AM
facebook twitter linkedin

U.S. stocks are slightly lower this morning, despite rising crude oil futures. Among equities in focus are chemical giant DuPont (NYSE:DD), drugmaker Celldex Therapeutics, Inc. (NASDAQ:CLDX), and semiconductor stock Marvell Technology Group Ltd. (NASDAQ:MRVL).

  • CLDX decided to halt the Phase 3 study of its brain cancer vaccine, Rintega, on the recommendation of an independent panel. As a result, the stock has lost over half its value out of the gate to trade at $3.89, and earlier hit a roughly four-year low of $3.70. The shares have now fallen over 86% in the past 12 months, bringing short sellers to the table -- as short interest now represents over one-fourth of Celldex Therapeutics, Inc.'s float. If bullish analysts continue to throw in the towel, even more losses could be in store. This morning, Guggenheim lowered its opinion to "neutral" from "buy," while Oppenheimer downgraded its rating to "perform" from "outperform."
  • MRVL has popped 2.4% out of the gate to $9.98, after The New York Post reported the company is open to selling itself. After spending several months bouncing mostly between $8 and $9, the shares have broken out to the upside, gaining 35% since their three-year low of $7.40 on Jan. 20. Marvell Technology Group Ltd. could extend this rally if bearish sentiment unwinds in the options pits. MRVL's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands at 1.08 -- just 2 percentage points from an annual high. 
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report


Special Offers from Schaeffer's Trading Partners